scholarly journals The Role of DLLs in Cancer: A Novel Therapeutic Target

2020 ◽  
Vol Volume 13 ◽  
pp. 3881-3901 ◽  
Author(s):  
Meng-Xi Xiu ◽  
Yuan-Meng Liu ◽  
Bo-hai Kuang
Keyword(s):  
Therapeutic Target ◽  
Novel Therapeutic

Molecular Interactions of α-Synuclein, Mitochondria, and Cellular Degradation Pathways in Parkinson's Disease

2020 ◽  
pp. 212-234
Author(s):  
Mansi Verma ◽  
Sujata Basu ◽  
Manisha Singh ◽  
Rachana R. ◽  
Simrat Kaur ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Interactions ◽  
Therapeutic Target ◽  
Molecular Mechanisms ◽  
Degradation Pathways ◽  
Functional Changes ◽  
The World ◽  
Novel Therapeutic

Parkinson's disease (PD) has been reported to be the most common neurodegenerative diseases all over the world. Several proteins are associated and responsible for causing PD. One such protein is α-synuclein. This chapter discusses the role of α-synuclein in PD. Various genetic and epigenetic factors, which cause structural and functional changes for α-synuclein, have been described. Several molecular mechanisms, which are involved in regulating mitochondrial and lysosomal related pathways and are linked to α-synuclein, have been discussed in detail. The knowledge gathered is further discussed in terms of using α-synuclein as a diagnostic marker for PD and as a novel therapeutic target for the same.

scholarly journals Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target

2019 ◽  
Vol 19 (1) ◽  
pp. 187-198 ◽  
Author(s):  
Toshihiro Kushibiki ◽  
Toru Nakamura ◽  
Masumi Tsuda ◽  
Takahiro Tsuchikawa ◽  
Koji Hontani ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Therapeutic Target ◽  
Novel Therapeutic

Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target

2015 ◽  
Vol 71 ◽  
pp. 190-193 ◽  
Author(s):  
Qingjun Pan ◽  
Caina Gao ◽  
Yanwen Chen ◽  
Yongmin Feng ◽  
Wei Jing Liu ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Therapeutic Target ◽  
Systemic Lupus ◽  
Novel Therapeutic

scholarly journals The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Quan Dong Nguyen ◽  
Jeffrey S. Heier ◽  
Diana V. Do ◽  
Adam C. Mirando ◽  
Niranjan B. Pandey ◽  
...  
Keyword(s):  
Macular Edema ◽  
Vascular Permeability ◽  
Signaling Pathway ◽  
Therapeutic Target ◽  
Vascular Diseases ◽  
Age Related Macular Degeneration ◽  
Vegf Receptor ◽  
Therapeutic Benefits ◽  
Novel Therapeutic

Abstract Background Retinal vascular diseases such as neovascular age-related macular degeneration, diabetic retinopathy and/or diabetic macular edema, and retinal vein occlusion with macular edema—share several key pathophysiologic aspects including neovascularization, vascular permeability, and inflammation. The role of vascular endothelial growth factor (VEGF) in these processes, and the therapeutic benefits of VEGF inhibition, have been well characterized. Anti-VEGF therapy is highly effective for many patients but is not uniformly effective in all patients and imposes a significant treatment burden. More recently, the role of the Tie2 signaling pathway in the pathophysiology of retinal vascular diseases has been investigated, and the Tie2 pathway represents a novel therapeutic target for these conditions. Areas covered The index review describes the Tie2 pathway and its complementary role to the VEGF pathway in the angiogenesis cascade and will summarize studies of molecules in development to therapeutically modulate the Tie2 pathway in retinal vascular diseases. Conclusions Activation of the Tie2 pathway leads to downstream signaling that promotes vascular health and stability and decreases vascular permeability and inflammation. AXT107 is a collagen IV–derived synthetic peptide with a dual mechanism of action that involves suppression of VEGF signaling and activation of the Tie2 pathway; these actions are accomplished by AXT107 binding to and disrupting different integrin, leading to blockade of the VEGF receptor and rearrangement of cellular Tie2 rendering it susceptible to Ang2 agonism. Other Tie2 agonist compounds are also in development, including faricimab and razuprotafib. Tie2 activation only modestly impacts angiogenesis on its own but significantly potentiates VEGF suppression. Co-regulation of the VEGF and Tie2 signaling pathways has the potential to improve functional and structural outcomes in eyes with retinal vascular diseases.

scholarly journals Emerging Role of the NLRP3 Inflammasome and Interleukin-1β in Neonates

Neonatology ◽  
2020 ◽  
pp. 1-10
Author(s):  
Murwan Omer ◽  
Ashanty Maggvie Melo ◽  
Lynne Kelly ◽  
Emma Jane Mac Dermott ◽  
Timothy Ronan Leahy ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Nlrp3 Inflammasome ◽  
Therapeutic Target ◽  
Inflammasome Activation ◽  
Neonatal Brain ◽  
Persistent Inflammation ◽  
Attractive Therapeutic Target ◽  
Clinical Models ◽  
Novel Therapeutic

Infection and persistent inflammation have a prominent role in the pathogenesis of brain injury and cerebral palsy, as well as other conditions associated with prematurity such as bronchopulmonary dysplasia. The NLRP3 inflammasome-interleukin (IL)-1β pathway has been extensively studied in adults and pre-clinical models, improving our understanding of innate immunity and offering an attractive therapeutic target that is already contributing to clinical management in many auto-inflammatory disorders. IL-1 blockade has transformed the course and outcome of conditions such as chronic infantile neurological, cutaneous, articular (CINCA/NOMID) syndrome. Inflammasome activation and upregulation has recently been implicated in neonatal brain and lung inflammatory disease and may be a novel therapeutic target.

scholarly journals Delineating the Role of TRP Channels in Metabolic Disease (P10-083-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Yan Qin Tan ◽  
Lai Kwok Leung
Keyword(s):  
Diabetes Mellitus ◽  
Western Blotting ◽  
Therapeutic Target ◽  
Adipocyte Differentiation ◽  
Metabolic Diseases ◽  
Trp Channels ◽  
Maturation Process ◽  
Novel Therapeutic

Abstract Objectives The objective of the present study is to elucidate the role of Transient Receptor Potential (TRP) channels in the process of adipogenesis and diabetes mellitus, in hopes of getting more understanding of the role of TRP channels in the process as well as in hopes of discovering a novel therapeutic target against metabolic diseases. Methods The role of TRP channels in adipogenesis and diabetes mellitus was investigated by using in vivo (C57/BL6J mice) and in vitro (3T3-L1 cells). The expressions of TRP isoforms were studied by using RT-PCR and western blotting assay. TRP channels agonist and antagonist were used to study the role of TRP channels while fat accumulation in cells was visualized by Oil Red O staining. Intracellular calcium inflow was estimated by confocal microscopy. Results Among the TRP channels screened, the authors identified the differential expressions of TRPC isoforms by using in vivo model. The results were further confirmed by using western blotting analysis. The changes in expression suggested the importance of the specific isoforms in the adipogenesis process. The agonist-antagonist study illustrated that the treatment of TRPC antagonists induced the maturation process while TRPC agonist attenuated adipocyte differentiation of 3T3-L1 cells. Conclusions The present study serves to illustrate the role of TRP channels in adipocyte biology. In conclusion, the current study demonstrated that the TRPC isoforms have differential expression during the maturation process of fat. Further, the modulation of TRPC could affect the adipocyte differentiation of 3T3-L1 cells. The understanding of TRPC channels in adipocyte biology serves as a novel therapeutic target against metabolic diseases such as obesity and diabetes mellitus. Funding Sources The research is funded by The Chinese University of Hong Kong Direct Grant. Supporting Tables, Images and/or Graphs

scholarly journals Hypoxic Regulation of Neutrophils in Cancer

2019 ◽  
Vol 20 (17) ◽  
pp. 4189 ◽  
Author(s):  
Daniel Triner ◽  
Yatrik M. Shah
Keyword(s):  
Transcription Factors ◽  
Therapeutic Target ◽  
Human Cancer ◽  
Critical Role ◽  
Neutrophil Function ◽  
Neoplastic Progression ◽  
Specific Expression ◽  
Microbial Response ◽  
Novel Therapeutic

Neutrophils have been well-characterized for their role in the host anti-microbial response. However, it is now appreciated that neutrophils have a critical role in tumorigenesis and tumor progression in the majority of solid tumors. Recent studies have indicated a critical role for hypoxia in regulating neutrophil function in tumors. Furthermore, neutrophil-specific expression of hypoxia-inducible transcription factors may represent a novel therapeutic target for human cancer. In this review, we highlight the function of neutrophils in cancer and the role of the neutrophil hypoxic response in regulating the neoplastic progression of cancer.

Sign in / Sign up

Export Citation Format

Share Document